Drug Trial Radar · NCT01910259
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Last checked: Nov 20, 2026Latest source record: Mar 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
445
Actual
Start
Dec 18, 2014
Primary completion
Jun 14, 2018
Study completion Jul 4, 2018
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medical Research Council; National Institute for Health Research, United Kingdom; National Multiple Sclerosis Society; University of Edinburgh; Queen Mary University of London; Keele University; University of Sheffield; University of Leeds; University of Warwick
- First posted
- Jul 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple sclerosis (MS) is a disabling and progressive neurological disease that affects approximately 100,000 people in the UK. Many patients with MS experience two phases of disease; early MS (also called relapsing remitting MS, RRMS) and late MS (also called secondary progressive MS (SPMS). Early MS is due to inflammation of the nerves and the insulation (called myelin) that surrounds the nerves. Early MS is often characterised by periods of "attacks" interspersed with periods of "remission" with no or low disease symptoms. Late or progressive MS, which affects the majority of patients and typically emerges after 10-15 years of disease, results from actual nerve death (also called neurodegeneration). The progressive stage of disease results not in individual attacks but slow, cumulative and irreversible disability affecting walking, balance, vision, cognition, pain control, bladder and bowel function. Critically, and unlike early disease, there is no proven treatment for the late stage of MS. This is therefore an urgent and major unmet health need. MS-SMART directly addresses this need and will evaluate in this clinical trial three drugs (fluoxetine, riluzole or amiloride), all of which have shown some promise in MS, and in particular in SPMS. The trial is randomised and blinded. Randomisation means patients can get any one of the three active drugs or the inactive placebo/dummy; blinded means that neither patients nor the doctors will know which drug or placebo patients are receiving. Randomisation and blinding are standard approaches in clinical trials to ensure unbiased testing of drugs. All patients in MS-SMART will have periodic MRI (magnetic resonance imaging) brain scans and after 96 weeks these will be analysed. We will then compare the scans of each drug to the placebo or dummy to see if any of the drugs slow the rate of brain shrinkage that normally occurs in SPMS. This measured change in brain size is the primary (major) outcome of MS-SMART.
Conditions
- Secondary Progressive Multiple Sclerosis
Interventions
AmilorideDrug
Comparison with placebo
RiluzoleDrug
Comparison with placebo
FluoxetineDrug
Comparison with placebo
PlaceboDrug
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- MRI-derived Percentage Brain Volume Change (PBVC).Time frame: 2 years
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Anne Rowling Regenerative Neurology Clinic, Royal Infirmary of Edinburgh
Edinburgh, United Kingdom
Gartnavel Royal Hospital, 1055 Great Western Road
Glasgow, United Kingdom
Brighton and Sussex University Hospitals
Haywards Heath, United Kingdom
St James's University Hospital
Leeds, United Kingdom
The Walton Centre
Liverpool, United Kingdom
The National hospital for Neurology and Neurosurgery, University College London
London, United Kingdom
The Royal Victoria Infirmary
Newcastle, United Kingdom
Queens Medical Centre
Nottingham, United Kingdom
John Radcliffe Hospital, Oxford University Hospitals NHS Trust
Oxford, United Kingdom
Derriford Hospital
Plymouth, United Kingdom
Royal Hallamshire Hospital
Sheffield, United Kingdom
University Hospital of North Staffordshire
Stoke-on-Trent, United Kingdom
Royal Cornwall Hospital
Truro, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.